The recent clinical results are reviewed of stereotactic radiosurgery/radiotherapy for the treatment of pituitary adenomas. The outcomes of pituitary adenomas treated by stereotactic radiosurgery/radiotherapy with gamma knife, CyberKnife, or linear accelerator (LINAC) radiosurgery were evaluated from articles published after 2004. Each study was evaluated for the number of patients, radiosurgical parameter (marginal dose), length of follow up, tumor growth control, rate of hormonal normalization in secretary adenomas, and adverse events. After gamma knife radiosurgery, the tumor reduction rates varied from 42.3% to 89% in non-secreting adenomas. However, the tumor control rates in non-secreting adenomas were more than 90% in most studies. In growth hormone-secreting adenomas, the rates of insulin-like growth factor-1 normalization ranged from 36.9% to 82%. In adrenocorticotropin-secreting adenomas, the rates for 24-hour urine free cortisol normalization ranged from 27.9% to 54%. In prolactin-secreting adenomas, the prolactin normalization ranged from 17.4% to 50%. New hormonal deficits ranged from 0% to 34%. New visual deficits were relatively low. The number of patients treated with CyberKnife and LINAC radiosurgery/radiotherapy was small and follow-up periods were relatively short compared to those with gamma knife treatment, but the clinical outcomes after these therapies were similar to those after gamma knife therapy. Image-guided stereotactic radiosurgery/radiotherapy with the gamma knife, CyberKnife, or LINAC system is effective and safe against pituitary adenomas. Careful long-term follow up of the patients is necessary because of longterm anti-tumor effects and delayed adverse events.
Introduction
Pituitary adenomas are very common intracranial tumors and account for 10-20% of all primary brain tumors. 16) Pituitary adenomas are classified into two groups: hormone-secreting tumors such as prolactin (PRL)-secreting adenomas, growth hormone (GH)-secreting adenomas, adrenocorticotropin (ACTH)-secreting adenomas, thyroid-stimulating hormonesecreting adenomas, and others, and non-functioning adenomas that do not secrete any biologically active hormones. Among pituitary adenomas, prolactinomas are commonly managed medically with dopamine agonists, and other types of tumors are commonly treated surgically. However, a small portion of prolactinomas are resistant to dopamine agonists, so other modalities of therapy are necessary. The other types of pituitary adenomas often show wide extrasellar extensions to the suprasellar region and cavernous sinus, and cannot be removed completely only by surgical treatments.
Leksell was the first to use the gamma knife to treat a pituitary adenoma patient in 1968. 16) Since then, stereotactic radiosurgery/radiotherapy has been applied to treating pituitary adenomas, and has achieved favorable tumor growth control and functional preservation. 8, 16) Stereotactic radiosurgery/ radiotherapy is one of the current methods of nonsurgical management for pituitary adenomas. A number of review articles about stereotactic radiosurgery/radiotherapy with a gamma knife for pituitary adenomas have been published. 8, 16, [21] [22] [23] In this review, we focus on the effectiveness and adverse effects of stereotactic radiosurgery/radiotherapy using the gamma knife, CyberKnife, and linear accelerator (LINAC) technology for pituitary adenomas, with particular focus on recent articles (after 2004). 
Non-functioning Adenomas
I. Gamma knife Recent radiographic outcomes of gamma knife radiosurgery (GKRS) for non-functioning adenomas are summarized in Table 1 . 4, 5, 13, 17, 19, 20, 25) Studies using GKRS have reported treatment plans with a marginal dose of 5 Gy to 35 Gy, and mean peripheral doses ranged from 14 Gy to 20 Gy. Mean follow-up periods ranged from 30 to 108 months. Tumor size decreased in 60% of patients and remained stable for 27% of patients, but 3% of patients had tumor growth outside the prescribed treatment volume, and the total tumor control rate was 95% at 3 and 7 years after radiosurgery. 25) GKRS resulted in 89% of treated tumors decreased in size with a median volume reduction of 61%, 17) and tumor control rates of more than 90%. 5, 20) Thus, most studies reported more than 90% tumor control rate with a mean follow-up period of 4 to 5 years. Non-functioning adenomas showed higher control rates than did functional adenomas, even with lower dose treatment. 13) Anterior pituitary function deterioration was often reported as an adverse effect of treatment in 2.8-32% of patients. The risk of deterioration of visual function due to radiation was very low, apparently because the radiation dose to the optic pathway was less than 10 Gy in most studies.
II. CyberKnife
CyberKnife radiosurgery/radiotherapy (CKRS/ CKRT) has been used for pituitary adenomas. 3, 11, 12, 28) In our previous study, 14 non-functioning adenomas were treated with CyberKnife surgery. 11) In all cases, fractionated stereotactic radiosurgery was performed. The marginal radiation dose for single-dose radiosurgery was calculated by the linear-quadratic formula using LQ-Model (a/b ＝ 2). The marginal radiation doses ranged from 12.0 Gy to 13.2 Gy (mean 12.6 Gy). The pre-treatment tumor size ranged from 2.1 cm 3 to 34.9 cm 3 (mean 13.3 cm 3 ). The follow-up period ranged from 21 to 40 months (mean 32.1 months). The tumor size after radiosurgery decreased in 1 patient (7.1%), and was unchanged in 12 patients (85.7%). The overall tumor control rate was 92.9% for non-functioning adenomas. One patient underwent additional resection 24 months after radiosurgery because of cystic expansion. Fourteen non-functioning adenomas were treated with CyberKnife surgery, and all tumors were controlled in size. 12) However, 2 cases of cystic expansion were reported, and we also noted cases of cystic expansion. 3) These studies demonstrated the effectiveness of CKRS/CKRT for pituitary adenomas, but the number of patients was limited and follow-up periods were not very long (mean 26-30 months). Neurol Med Chir (Tokyo) 50, September, 2010
Stereotactic Radiosurgery for Pituitary Adenomas III. LINAC-based radiosurgery/radiotherapy A study using LINAC radiosurgery showed 40.5% with partial response and 59.5% with stable tumor size among 37 non-functioning adenomas. 32) The tumor control rate was 100% with a mean follow-up period of 56.6 months.
GH-Secreting Adenomas I. Gamma knife
A number of reports about GKRS for GH-secreting adenomas have been published. 1, 2, 7, 10, 13, 14, 18, 24, 26, [29] [30] [31] 33) Descriptions of the endocrine and radiographic outcomes of GKRS for GH-secreting adenomas are summarized in Table 2 . In these studies, the mean follow-up periods ranged from 35 to 120 months. Peripheral radiation doses ranged from 18.9 Gy to 32 Gy. The most widely accepted criteria for hormonal remission in GH-secreting adenomas are GH level less than 1.0 ng/ml in response to the 75 g oral glucose tolerance test and normal serum insulin-like growth factor-1 (IGF-1) level matched for age and sex. IGF-1 normalization was often defined as hormonal normalization. 1, 7, 10, 18, 26, 29, 31, 33) Published hormonal normalization rates following GKRS for GHsecreting adenomas ranged from 36.9% to 82%. Although the rates of tumor shrinkage varied widely, from 11% to 92%, the majority of cases achieved tumor control (95.1-100%). This disparity may indicate differences in the definition of tumor shrinkage.
Anterior pituitary function deterioration was reported as an adverse effect of GKRS in 1.9-50% of patients. Most papers reported the risk of deterioration of visual function due to radiation was very low, but 1.3-11.1% of patients did have new visual deficits, including transient events. In GH-secreting adenomas, the radiation dose to the optic pathway was usually less than 10 Gy in most studies. 
II. CyberKnife
There are three reports of CKRS/CKRT for GHsecreting adenomas. 11, 12, 28) Nine cases of GH-secreting adenomas were treated with CyberKnife radiosurgery. 28) The marginal radiation dose was 21 Gy (mean). IGF-1 normalization was induced in 44.4% of patients, and tumor size was controlled in all patients. Four cases of GH-secreting adenomas were treated with fractionated stereotactic radiosurgery using 5 Gy × 5 fractions. 12) IGF-1 normalization was induced in 50% of patients, and tumor size was controlled in all patients. We experienced only one case of GH-secreting adenoma. 11) In this case, the marginal radiation doses were 11.8 Gy. The IGF-1 level was markedly decreased but did not reach a normal level. Tumor size was controlled. The follow-up period from these 3 studies ranged from 25.4 to 52 months.
Anterior pituitary function deterioration occurred as an adverse effect in 33% of patients. 28 ) Five percent of patients had new visual deficits including transient events. 12) These studies demonstrated similar effectiveness of CKRS/CKRT for GH-secreting adenomas, but the number of patients was limited and follow-up periods were not very long (mean 25.2-52 months).
III. LINAC-based radiosurgery/radiotherapy
A study using LINAC radiosurgery reported 64 cases of GH-secreting adenomas. 32) In their study, the marginal radiation dose was 15.5 Gy (mean). The results were 49.8% of IGF-1 normalization, 23.4% of tumor size response, and 96.9% of tumor size control with a mean follow-up period of 56.6 months.
However, 12.3% of new hormonal deficit occurred, although data included other types of functioning adenoma treatments.
ACTH-Secreting Adenomas I. Gamma knife
Several reports about GKRS for ACTH-secreting adenomas have been published since 2004. 1, 6, 13, 24, 30, 33) Endocrine and radiographic outcomes of GKRS for ACTH-secreting adenomas are summarized in Table 3 . In these studies, mean follow-up periods ranged from 37 to 94 months. Peripheral radiation doses ranged from 21.4 Gy to 28.7 Gy. Endocrinological remission was obtained in 27.9% to 54% of the patients. In most studies, endocrinological remission was defined as 24 hours of urine free cortisol (UFC) normalization. Patients with Cushing disease showed the best response because of the smallest tumor size with highest dose treatment. 13) With regard to tumor size, tumor control rates ranged from 89.7% to 100%. Moreover, 80% of tumors decreased in size. 6) Anterior pituitary function deterioration was reported as an adverse effect in 1.5-22% of patients. 1, 6, 33) Most papers reported that the risk of deterioration of visual function due to radiation was very low (1.3-5.6%) in patients with ACTH-secreting adenomas.
II. CyberKnife
We were only able to obtain data of CKRS/CKRT for ACTH-secreting adenomas from our own study. 11) In our study, 3 cases were treated and fol- Anterior pituitary function deterioration was observed as an adverse effect in one patient (33.3%) treated with high-dose radiation. No visual deterioration due to radiation was observed.
III. LINAC-based radiosurgery/radiotherapy
A study using LINAC radiosurgery reported 17 cases of ACTH-secreting adenomas. 32) The marginal radiation dose was 16.4 Gy (mean). The results were 52.9% of 24-hour UFC normalization, 19.5% of tumor size response, and 88.2% of tumor size control with a mean follow-up period of 58.7 months. 32)
PRL-Secreting Adenomas I. Gamma knife
The first choice of treatment for PRL-secreting adenomas is medical and/or surgical treatment. Radiosurgery for PRL-secreting adenomas is usually used after failure of these treatments. Several articles have been published about the treatment of PRL-secreting adenomas with GKRS since 2006. 1, 9, 13, 24, 27, 30, 33) Endocrine and radiographic outcomes of GKRS for PRL-secreting adenomas are summarized in Table 4 . In these studies, mean follow-up periods ranged from 19.5 to 86.2 months.
Peripheral radiation doses ranged from 18.6 Gy to 34 Gy. Endocrinological remission was obtained in 17.4% to 46.6% of the patients. In most studies, endocrinological remission was defined as PRL normalization without medication such as dopamine agonists. Tumor volume reduction was observed in 46-84.6% of the patients with PRL-secreting adenomas, and tumor control rates ranged from 89% to 100%.
Anterior pituitary function deterioration was reported as an adverse effect in 0-28% of patients. Most papers reported the risk of deterioration of visual function due to radiation was very low (1.3-7%) in patients with PRL-secreting adenomas.
II. CyberKnife
The data of CKRS/CKRT for PRL-secreting adenomas was obtained from 2 studies, including ours. 11, 12) In our study, 3 cases were treated and followed up for mean 30 months. Peripheral radiation doses ranged from 9.4 Gy to 22.2 Gy (mean 14.4 Gy). Endocrinological remission was obtained in one (33%) of the patients. The tumor size shrank in 2 cases (66.7%) and was controlled in all cases. 11) Only 1 case of PRL-secreting adenoma was treated with 5 Gy × 5 fractions. 12) Tumor size was controlled, but the patient required cabergoline therapy.
No anterior pituitary function deterioration or visual deterioration due to radiation were observed in our study.
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III. LINAC-based radiosurgery/radiotherapy
A study using LINAC radiosurgery reported 13 cases of PRL-secreting adenomas. 32) The marginal radiation dose was 13.5 Gy (mean). The results were 52.9% of 24-hour PRL normalization, 38.5% of tumor size response, and 100% of tumor size control with a mean follow-up period of 56 months.
Comparison of Conventional External
Radiotherapy and Stereotactic Radiosurgery/Radiotherapy (SRS/SRT) Long-term results were reported of 125 consecutive patients treated in a single institution. 15) Single-dose radiosurgery more promptly produced an effect on the hypersecretion of pituitary hormones and may be recommended over fractionated radiotherapy for suitable patients. 15 ) Stereotactic conformal radiotherapy is a suitable treatment technique for all sizes of pituitary adenoma and the efficacy of this treatment is comparable to that of conventional radiotherapy, but there is no information on potential reduction in the incidence of late radiation-induced toxicity because of the lack of long-term follow up in the recent review. 21) Single-fraction SRS could only be safely delivered to small tumors away from critical structures. There is no evidence that SRS produces a faster decline of elevated hormone levels than fractionated treatment, and SRS is not associated with lesser morbidity. Based on the present evidence, it is not possible to conclude that SRS/SRT techniques are more effective or safer than conventional radiotherapy in non-functioning adenomas. 22) Further studies including long-term clinical results are necessary for the comparison of the results with these techniques.
Conclusions
In this review article, we summarize the recent clinical results of image-guided SRS/SRT with the gamma knife, CyberKnife, and LINAC systems from articles published after 2004. The follow-up periods were more than 5 years in most articles about gamma knife surgery. The clinical outcomes of gamma knife surgery indicate that this technique is effective and safe against pituitary adenomas, which agrees with the data reported before 2004. CKRS/CKRT and LINAC radiosurgery are also effective and safe against pituitary adenomas. The clinical outcomes after these therapies are similar to those following gamma knife surgery, but the number of patients reported is small and follow-up periods are relatively short compared to the data on patients receiving gamma knife surgery. The incidence of pituitary dysfunction as an adverse effect varies but is relatively frequent, whereas visual dysfunction is rare after radiosurgery. Careful long-term follow up of the patients is necessary because of long-term antitumor effects and delayed adverse events.
